ONT-380 has stage IV HER2+ breast cancer patient 'worrying about normal stuff again'

Promising clinical trial results show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.

Read the whole article on Science Daily

More from Science Daily